Research
Hormonal
Semaglutide, a GLP-1 receptor agonist, can lead to weight reductions of up to 15%.
Practitioners should consider the potential effectiveness of semaglutide for weight loss in patients.
StrongSupportsmedium confidence
The introduction of semaglutide, a glucagon-like-1 receptor agonist (GLP-1ra) as a weight-loss medication, has attracted considerable public and medical attention, reporting weight reductions of up to 15%.
Why this rating
The study is based on ethnographic fieldwork, providing direct observational evidence.
Source
Tinkering with weight loss medication in clinical encounters: An ethnographic study
Sissel Due Jensen et al. · Social Science & Medicine · 2025
DOI 10.1016/j.socscimed.2025.118538
otherCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →